An In-Depth Overview of Interstitial Lung Diseases for Healthcare Professionals
OthersPage Navigation
Introduction
Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 conditions characterized by inflammation and fibrosis of the lung interstitium, leading to progressive dyspnea and cough.
Etiology and Classification
ILDs can be idiopathic, related to systemic diseases, or due to environmental exposures. The most common idiopathic ILD is idiopathic pulmonary fibrosis (IPF). Other forms include nonspecific interstitial pneumonia and sarcoidosis.
Clinical Manifestations and Diagnosis
Patients typically present with progressive dyspnea and dry cough. Physical examination may reveal crackles and clubbing. High-resolution CT is the gold standard for diagnosis. Pulmonary function tests show a restrictive pattern and reduced diffusion capacity.
Treatment and Prognosis
Treatment is largely supportive, including oxygen therapy and pulmonary rehabilitation. Antifibrotic drugs like pirfenidone and nintedanib are approved for IPF. Prognosis varies widely, with IPF having a median survival of 2-3 years post-diagnosis.
Conclusion
ILDs are complex disorders requiring a thorough understanding for effective management. Further research is needed to develop more effective treatments and improve patient outcomes.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge